Zentalis Pharmaceuticals, Inc. (ZNTL)

USD 1.42

(4.43%)

Annual Income Statements

(In USD)
Breakdown 2023 2022 2021 2020 2019 2018
Revenue - - - - - 14 Thousand
Cost of Revenue 1.38 Million 1.42 Million 544 Thousand 160 Thousand 111 Thousand -
Gross Profit -1.38 Million -1.42 Million -544 Thousand -160 Thousand -111 Thousand 14 Thousand
Operating Expenses 252.55 Million 227.28 Million 216.54 Million 118.78 Million 46.84 Million 23.79 Million
Selling, General and Administrative Expenses 59.39 Million 54.55 Million 40.94 Million 33.88 Million 8.45 Million 4.87 Million
Research and Development Expenses 189.59 Million 172.73 Million 175.6 Million 84.9 Million 38.38 Million 18.92 Million
Other Expenses - - - - -16 Thousand -
Cost and Expenses 253.94 Million 227.28 Million 216.54 Million 118.78 Million 46.84 Million 23.79 Million
Operating Income -248.98 Million -227.28 Million -216.54 Million -118.78 Million -46.84 Million -23.78 Million
Interest Expense - 2.57 Million - - - -
Income Tax Expense -601 Thousand -469 Thousand -297 Thousand 444 Thousand 15 Thousand 4000.00
Earnings before Tax -276.89 Million -221.3 Million -164.55 Million -118.1 Million -46.36 Million -23.42 Million
Net Income -292.19 Million -220.83 Million -164.26 Million -118.54 Million -46.37 Million -21.06 Million
Earnings Per Share Basic -4.47 -4.18 -3.85 -2.89 -1.29 -1.17
Earnings Per Share Diluted -4.47 -4.18 -3.85 -2.89 -1.29 -1.17
Weighted Average Shares Outstanding 65.4 Million 52.85 Million 42.68 Million 41.04 Million 35.87 Million 18.05 Million
Weighted Average Shares Outstanding (Diluted) 65.4 Million 52.85 Million 42.68 Million 41.04 Million 35.87 Million 18.05 Million
Gross Margin - - - - - 1.00
EBIT Margin - - - - - -1695.14
Profit Margin - - - - - -1504.79
EBITDA -275.5 Million -219.87 Million -164.01 Million -117.94 Million -46.73 Million -23.73 Million
Earnings Before Tax Margin - - - - - -1698.79

Income Statement Charts